Skip to main content
Clinical Trials/JPRN-UMIN000013867
JPRN-UMIN000013867
Not yet recruiting
未知

Study of renal function renal protective effect of cooling method in laparoscopic partial nephrectomy - Study of renal cooling method in laparoscopic partial nephrectomy

Kansai Medical University0 sites30 target enrollmentMay 2, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Renal cell cacinoma
Sponsor
Kansai Medical University
Enrollment
30
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 2, 2014
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Piece renal patients

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
The investigation of the renal protective effect of Carperitide(hANP:human atrial natriuretic peptide) during adult living donor renal transplantation, a single center experience.living donor renal transplantation
JPRN-UMIN000014279Toho University School of Medicine, Department of Anesthesiology30
Completed
Not Applicable
Examination of the effect of renal protection of aliskiren in chronic renal failure patient with hypertension (preservation period)Chronic renal failure patient with hypertension under going rennin-angiotensin treatment (ARB/ACE-inhibitor) (preservation period)
JPRN-UMIN000002478Kure Kyousai Hospital200
Completed
Not Applicable
A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failurechronic heart failure, chronic kidney disease
JPRN-UMIN000036119Kawashima hospital40
Recruiting
Not Applicable
Examination of the effects on renal function and prognosis of various diuretics for liver cirrhosisiver cirrhosis
JPRN-UMIN000040179Hokkaido University400
Active, not recruiting
Phase 1
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2014-005033-31-FRAddmedica S.A.S